Search

Aim: Elderly women are reported to have worse postural balance in the mediolateral direction than elderly men, which may be related to hip lateral muscle properties. The purpose of this study was to investigate the effects of sex, age and their interactions on hip abductor muscle properties. Methods: Thirty elderly and 30 young healthy subjects were recruited in this study. Subjects were instructed to abduct their leg as forcefully and quickly as possible under isometric condition, in response to audible beeps. Electromyogram was measured on the gluteus medius muscle and abduction torque was measured. Investigated muscle properties included torque amplitudes and muscle contraction timings. Muscle contraction timings were designated as premotor time, electromechanical delay and total reaction time. The effects of sex, age and their interactions on muscle properties were analyzed. Results: Women showed smaller torque amplitudes, longer electromechanical delay and longer total reaction time than men (P < 0.01), whereas no sex difference was observed in association with premotor time (P = 0.15). Age-sex interaction was significant in torque amplitudes and in electromechanical delay (P < 0.01). Post-hoc test revealed that torque amplitude differed between sexes only in the young (P < 0.001). In contrast, the electromechanical delay differed between sexes only in the elderly and the age-related elongation of electromechanical delay was significant only in women (P < 0.001). Conclusion: Both a sex difference and a sex difference of age-related change in hip abductor muscle properties were demonstrated. These sex differences may contribute to the sex difference in lateral balance performance. [ABSTRACT FROM AUTHOR]

Background: The aim of this phase II study was to determine the efficacy of gemcitabine plus cisplatin chemotherapy in patients with advanced biliary tract cancer. Methods: Eligibility criteria included histologically confirmed adenocarcinoma with measurable tumor in the biliary tract that was unresectable and either locally advanced or metastatic. Patients received a combination of gemcitabine (1000 mg/m2 intravenously [IV] on days 1, 8, and 15) and cisplatin (75 mg/m2 IV on day 1). Cycles were repeated every 28 days. Objective tumor response rates and toxicities were evaluated according to World Health Organization criteria. Results: Twenty-seven patients were enrolled in the study and a total of 120 cycles of chemotherapy were administrated. Objective partial response was observed in nine (33.3%) patients, while stable disease was found in seven (25.9%) patients. The median survival time was 10.0 months and the 1-year survival rate was 36%. Median time to disease progression was 5.6 months. The most common grade 3–4 toxicities were leukopenia (25.9%), anemia (29.6%), thrombocytopenia (22.2%), and vomiting (18.5%). Only one patient was hospitalized for chemotherapy-related complications. Conclusion: Gemcitabine and cisplatin combination chemotherapy is an effective, safe, and well-tolerated regimen for the treatment of advanced biliary tract cancer. [ABSTRACT FROM AUTHOR]